THE HEALTH ASSESSMENT QUESTIONNAIRE
Stanford University School of Medicine
Division of Immunology & Rheumatology
INTRODUCTION
The Health Assessment Questionnaire (HAQ) was originally developed in 1978 by James F. Fries, MD,
and colleagues at Stanford University. It was one of the first self-report functional status (disability) measures and
has become the dominant instrument in many disease areas, including arthritis. It is widely used throughout the
world and has become a mandated outcome measure for clinical trials in rheumatoid arthritis and some other
diseases.
The initial paper, published in 1980 (see key journal references at end of this document), has been the most
cited article in the rheumatology literature. A 1995 review discusses more that 200 publications on the reliability,
validity, and its applicability in multiple settings and languages. The present number of citations (see website-to be
completed in September, 2000) is in excess of 400.
Purpose
The HAQ was developed as a comprehensive measure of outcome in patients with a wide variety of
rheumatic diseases, including rheumatoid arthritis, osteoarthritis, juvenile rheumatoid arthritis, lupus, scleroderma,
ankylosing spondylitis, fibromyalgia, and psoriatic arthritis. It has also been applied to patients with HIV/AIDS and
in studies of normal aging. It should be considered a generic rather than a disease-specific instrument. Its focus is
on self-reported patient-oriented outcome measures, rather than process measures.
User Permission
The HAQ is copyrighted only so that it will be used unmodified, thus preserving the validity of results, and
so that we retain a record of use. However, we consider the HAQ to be in the public domain, with the request that
users cite relevant HAQ article(s) in their publications (see key journal references at the end of this document and
the website for complete articles). There is no charge for permission.
General Questionnaire Description
While the HAQ disability and pain scales are often referred to as “The HAQ”, long term outcome
assessment best includes the Full Five-Dimension HAQ, which is a comprehensive outcome measure that assesses a
hierarchy of patient outcomes in four domains: 1) disability, 2) discomfort and pain, 3) drug side effects (toxicity)
and 4) dollar costs. Death, while obviously not a self-report outcome, is a requisite part of the conceptual model of
patient outcome. In the United States, this is usually accomplished using the National Death Index. Alternatively,
the first two domains, which comprise the HAQ Disability Index and Pain Scale can be used independently and
frequently are. The drug toxicity sections and the economic impact sections undergo periodic changes; the
disability, pain, and patient global areas have been maintained as constant since 1983.
The domain of disability is assessed by the eight categories of dressing, arising, eating, walking, hygiene,
reach, grip, and common activities. Discomfort is determined by the presence of pain and its severity. Specific
drug-associated side effects are classified according to their severity and whether the drug was stopped. Dollar costs
are divided into direct and indirect costs. Direct costs include hospitalization, surgery, nursing home care, physician
and health worker visits, medications, laboratory tests, x-rays, aids and devices, non-traditional treatments,
assistance with personal care, housework and such, transportation and any additional cost related to medical care.
Utilization of these services is determined and converted into dollar costs. Indirect costs are those associated with
productive days lost for the employed, housewives, students and retired persons, and changes in lifestyle and
activities for the patient and family. Items address normal daily activities, employment status, marital status, and
living arrangements.
IMACS Form 04a: Instructions for the Health Assessment Questionnaire
2